

Q3

**Quarterly
REPORT**



SAVARIA CORPORATION

Quarterly Report

For the Three-Month and Nine-Month Periods Ended September 30, 2025

SAVARIA CORPORATION

Management's Discussion & Analysis Report

For the three-month and nine-month periods ended September 30, 2025

Contents

- | | |
|---------------------------------|---|
| 1. Basis of Presentation | 8. Financial Position |
| 2. Forward-Looking Statements | 9. Liquidity |
| 3. IFRS and Non-IFRS Measures | 10. Governance |
| 4. Business Overview | 11. Material Accounting Policies and Estimates |
| 5. Financial Highlights | 12. Risks and Uncertainties |
| 6. Financial Review | 13. Environmental, Social and Governance ("ESG") Values |
| 7. Summary of Quarterly Results | 14. Outlook |

1. Basis of Presentation

The following management's discussion and analysis ("MD&A"), dated November 5, 2025, is intended to assist readers to better understand Savaria Corporation, its business context, strategies, risk factors and key financial results. It notably discusses the Corporation's financial position and operating results for the three-month and nine-month periods ended September 30, 2025, in comparison to the corresponding periods of fiscal 2024. Unless otherwise indicated, the terms "Corporation," "Savaria," "we" and "our," refer to Savaria Corporation and its subsidiaries.

Prepared in accordance with *National Instrument 51-102 Respecting Continuous Disclosure Obligations*, this report should be read in conjunction with the unaudited interim condensed consolidated financial statements for the period ended September 30, 2025 as well as the audited consolidated financial statements and accompanying notes for the year ended December 31, 2024, and the MD&A for the same period. Unless otherwise indicated, all amounts are expressed in Canadian dollars. Amounts in certain passages of this MD&A may be expressed in millions of Canadian dollars ("M"); however, all percentage references related to such amounts are calculated based on the thousands of Canadian dollars amount figures contained in the corresponding tables.

The Corporation's management is responsible for the preparation of the MD&A, and it has been reviewed by Savaria's Audit Committee and approved by its Board of Directors.

Additional information, including the Annual Information Form, is available on the website of SEDAR+ at www.sedarplus.ca.

2. Forward-Looking Statements

This MD&A includes certain statements which are “forward-looking statements” within the meaning of the securities laws of Canada. Any statement in this MD&A which is not a statement of historical fact may be deemed to be a forward-looking statement. When used in this MD&A, the words “believe,” “could,” “should,” “intend,” “expect,” “estimate,” “assume” and other similar expressions are generally intended to identify forward-looking statements. It is important to know the forward-looking statements in this MD&A describe our expectations as at November 5, 2025, which are not guarantees of the future performance of Savaria or its industry, and involve known and unknown risks and uncertainties which may cause Savaria’s or the industry’s outlook, actual results or performance to be materially different from any future results or performance expressed or implied by such statements. Our actual results could be materially different from our expectations if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. A change affecting an assumption can also have an impact on other interrelated assumptions, which could increase or diminish the effect of the change. As a result, we cannot guarantee that any forward-looking statement will materialize and, accordingly, the reader is cautioned not to place undue reliance on these forward-looking statements. Forward-looking statements do not take into account the effect that transactions or special items announced or occurring after the statements are made may have on our business. For example, they do not include the effect of sales of assets, monetizations, mergers, acquisitions, other business acquisitions or transactions, asset write-downs or other charges announced or occurring after forward-looking statements are made.

Unless otherwise required by applicable securities laws, we disclaim any intention or obligation to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise.

The foregoing risks and uncertainties include the risks set forth under “Risks and Uncertainties” in this report, as well as other risks detailed from time to time in reports filed by Savaria with securities regulators in Canada.

3. IFRS and Non-IFRS Measures

The Corporation’s financial statements are prepared in accordance with IFRS. However, in this MD&A the following non-IFRS measures and non-IFRS ratios are used by the Corporation: EBITDA, adjusted EBITDA, adjusted EBITDA margin, adjusted EBITDA per share, adjusted net earnings, adjusted net earnings per share, available credit facilities, available funds, working capital, total debt, net debt and ratio of net debt to adjusted EBITDA. Reconciliations to IFRS measures and ratios can be found in sections 3, 6 and 8 of this MD&A.

The Corporation believes these non-IFRS measures and ratios are useful for investors and analysts to properly assess its financial and operating performance. Although management, investors and analysts use these measures and ratios to evaluate the Corporation’s financial and operating performance, they have no standardized definition in accordance with IFRS and should not be regarded as an alternative to financial information prepared in accordance with IFRS. These measures and ratios may therefore not be comparable to similar measures and ratios reported by other entities.

EBITDA

EBITDA is defined as earnings before net finance costs, income tax expense and depreciation and amortization. Management uses EBITDA to assess the operating performance of our business. The Corporation also believes this measure is commonly used by investors and analysts to measure a company’s ability to service debt and to meet other payment obligations, or as a common valuation measurement. The Corporation excludes depreciation and amortization expense, which is non-cash in nature and can vary significantly depending upon accounting methods or non-operating factors and net finance cost to eliminate the impact on earnings derived from non-operational activities. Investors are cautioned that EBITDA should not be considered an alternative to operating income or net earnings for the period as an indicator of the Corporation’s performance, or an alternative to cash flows from operating, investing and financing activities as a measure of liquidity and cash flow.

ADJUSTED EBITDA, ADJUSTED EBITDA MARGIN AND ADJUSTED EBITDA PER SHARE

Adjusted EBITDA is defined as EBITDA before other expenses or income, strategic initiatives expenses and stock-based compensation expense. Management uses adjusted EBITDA, adjusted EBITDA margin and adjusted EBITDA per share, among other measures, to assess the operating performance of the business. The Corporation also believes these measures are commonly used by investors and analysts to measure a company's ability to service debt and to meet other payment obligations, or as a common valuation measurement. The Corporation excludes depreciation and amortization expense as well as stock-based compensation expense, which are non-cash in nature and can vary significantly depending upon accounting methods or non-operating factors. Furthermore, the Corporation excludes a) Other expenses or income that can vary from period to period and which could otherwise mask the underlying trends in the business and b) Strategic initiatives expenses, which are significant costs incurred in relation to *Savaria One* that could mask the actual baseline performance, as the costs are only for the duration of the project and incurred prior to any perpetual benefits realized or pending realization. Investors are cautioned that adjusted EBITDA should not be considered an alternative to operating income or net earnings for the period as an indicator of the Corporation's performance, or an alternative to cash flows from operating, investing and financing activities as a measure of liquidity and cash flow.

Adjusted EBITDA margin is defined as adjusted EBITDA expressed as a percentage of revenue.

Adjusted EBITDA per share is calculated using the diluted weighted average number of shares for the corresponding period.

in thousands of dollars, except percentages and per- share amounts	Total	2025				2024			2023
	Trailing 12 months	Q3	Q2	Q1	Q4	Q3	Q2	Q1	Q4
Operating Income	\$97,417	\$27,695	\$26,712	\$21,238	\$21,772	\$22,040	\$22,604	\$17,721	\$19,843
Amortization and depreciation expense	54,318	13,790	13,381	13,238	13,909	13,471	12,547	12,262	12,319
EBITDA*	151,735	41,485	40,093	34,476	35,681	35,511	35,151	29,983	32,162
Stock-based compensation	2,844	752	647	728	717	766	683	590	403
Strategic initiatives expenses	19,469	4,672	4,607	4,670	5,520	5,413	5,347	5,299	2,018
Other expenses (income)	3,760	647	1,391	773	949	47	764	(1,191)	522
Adjusted EBITDA*	\$177,808	\$47,556	\$46,738	\$40,647	\$42,867	\$41,737	\$41,945	\$34,681	\$35,105
Adjusted EBITDA per share*	\$2.47	\$0.66	\$0.65	\$0.57	\$0.59	\$0.58	\$0.59	\$0.49	\$0.49
Diluted weighted average number of shares	-	72,160,540	71,858,056	71,868,735	72,357,117	71,811,980	71,405,637	71,213,393	71,031,225
Adjusted EBITDA Margin*	19.9%	21.2%	20.6%	18.5%	19.2%	19.5%	19.0%	16.6%	16.2%

* Non-IFRS measures are described and reconciled in this section.

in thousands of dollars, except percentages	Q3 2025			
	Accessibility	Patient Care	Head Office	Total
Operating Income	\$28,297	\$5,163	\$(5,765)	\$27,695
Amortization and depreciation expense	10,544	2,346	900	\$13,790
EBITDA*	\$38,841	\$7,509	\$(4,865)	\$41,485
Stock-based compensation	-	-	752	\$752
Strategic initiatives expenses	3,104	493	1,075	\$4,672
Other expenses	382	164	101	\$647
Adjusted EBITDA*	\$42,327	\$8,166	\$(2,937)	\$47,556
Adjusted EBITDA Margin*	23.5%	18.3%	n/a	21.2%
Q3 2024				
Operating Income	\$22,478	\$4,505	\$(4,943)	\$22,040
Amortization and depreciation expense	10,270	2,192	1,009	\$13,471
EBITDA*	\$32,748	\$6,697	\$(3,934)	\$35,511
Stock-based compensation	-	-	766	\$766
Strategic initiatives expenses	3,378	930	1,105	\$5,413
Other expenses (income)	91	-	(44)	\$47
Adjusted EBITDA*	\$36,217	\$7,627	\$(2,107)	\$41,737
Adjusted EBITDA Margin*	21.3%	17.4%	n/a	19.5%

* Non-IFRS measures are described and reconciled in this section.

in thousands of dollars, except percentages	YTD 2025			
	Accessibility	Patient Care	Head Office	Total
Operating Income	\$73,639	\$18,880	\$(16,874)	\$75,645
Amortization and depreciation expense	30,885	6,755	2,769	\$40,409
EBITDA*	\$104,524	\$25,635	\$(14,105)	\$116,054
Stock-based compensation	-	-	2,127	\$2,127
Strategic initiatives expenses	9,093	1,709	3,147	\$13,949
Other expenses	1,671	720	420	\$2,811
Adjusted EBITDA*	\$115,288	\$28,064	\$(8,411)	\$134,941
Adjusted EBITDA Margin*	21.9%	19.4%	n/a	20.1%
YTD 2024				
Operating Income	\$60,882	\$16,729	\$(15,246)	\$62,365
Amortization and depreciation expense	28,893	6,246	3,141	\$38,280
EBITDA*	\$89,775	\$22,975	\$(12,105)	\$100,645
Stock-based compensation	-	-	2,039	\$2,039
Strategic initiatives expenses	10,948	1,891	3,220	\$16,059
Other expenses (income)	(764)	-	384	\$(380)
Adjusted EBITDA*	\$99,959	\$24,866	\$(6,462)	\$118,363
Adjusted EBITDA Margin*	19.8%	17.7%	n/a	18.4%

* Non-IFRS measures are described and reconciled in this section.

ADJUSTED NET EARNINGS AND ADJUSTED NET EARNINGS PER SHARE

Adjusted net earnings is defined as net earnings excluding other expenses or income, strategic initiatives expenses and the related income tax effects. The Corporation uses adjusted net earnings and adjusted net earnings per share to measure its performance from one period to the next, without the variation caused by the impacts of the items described above. The Corporation excludes these items because they affect the comparability of its financial results and could potentially distort the analysis of trends in its business performance. The Corporation excludes a) Other expenses or income that can vary from period to period and which could otherwise mask the underlying trends in the business and b) Strategic initiatives expenses, which are significant costs incurred in relation to *Savaria One* that could mask the actual baseline performance, as the costs are only for the duration of the project and incurred prior to any perpetual benefits realized or pending realization.

Adjusted net earnings per share is calculated using the diluted weighted average number of shares for the corresponding period.

AVAILABLE CREDIT FACILITIES AND AVAILABLE FUNDS

Available credit facilities is defined as the total amount available under the existing revolving facility minus the amount drawn and outstanding letters of credit. Available funds is defined as the available credit facilities plus cash and cash equivalents. The Corporation believes that certain investors and analysts use these measures to assess financial leverage.

WORKING CAPITAL

Working capital is defined as current assets minus current liabilities. The Corporation uses this metric to measure its liquidity, operational efficiency and short-term financial health.

TOTAL DEBT, NET DEBT AND RATIO OF NET DEBT TO ADJUSTED EBITDA

Total debt is defined as the amount drawn under the revolving facility, notes payable related to business acquisitions, outstanding letters of credit and lease liabilities, including current portions. Net debt is defined as total debt, net of cash and cash equivalents. The ratio of net debt to adjusted EBITDA is calculated by dividing net debt by the trailing twelve months adjusted EBITDA. The Corporation believes that certain investors and analysts use these measures to assess financial leverage.

4. Business Overview

Savaria is one of the global leaders in the accessibility industry, providing solutions for the elderly and physically challenged to improve their comfort, mobility and independence. The Corporation has one of the most comprehensive product lines in the industry, split into two reportable segments, *Accessibility* and *Patient Care*.

Savaria designs, manufactures, distributes and installs accessibility equipment, such as elevators for home and commercial use, stairlifts for straight and curved stairs, vertical and inclined wheelchair lifts and dumbwaiters. In addition, Savaria manufactures and markets a comprehensive selection of pressure management products, medical beds, as well as an extensive line of medical equipment and solutions for the safe movement of patients, such as transfer, lifting and repositioning aids.

Savaria operates a global manufacturing network with four plants in Canada, two in the United States, one in Mexico, five in Europe, and two in China. The Corporation has direct sales offices in Canada, the United States, seven European countries and Australia. It also operates an extensive worldwide dealer network.

As at November 5, 2025, Savaria's workforce totaled approximately 2,500 employees worldwide.

4.1 REPORTABLE SEGMENTS OF THE CORPORATION

The business is structured into two reportable segments, *Accessibility* and *Patient Care* according to their respective addressable markets.

Accessibility

Through the *Accessibility* segment, Savaria designs, manufactures, distributes and installs a wide portfolio of accessibility products including commercial elevators, home elevators, stairlifts, platform lifts and dumbwaiters, for personal, residential or commercial applications. It also sells a wide variety of wheelchair accessible motor vehicles adapted for people with special needs. Savaria operates manufacturing facilities in Canada (Brampton and Surrey), the United States (Greenville), Mexico (Querétaro), Italy (Milan), the United Kingdom (Kingswinford and Birmingham), the Netherlands (Heerhugowaard) and China (Huizhou and Xiamen). Savaria products are sold worldwide through a network of approximately 1,500 dealers as well as through 28 company-owned direct sales offices, through which the Corporation also provides installation, repair and maintenance services. The Van-Action and Freedom Motors subsidiaries, which were sold on February 1, 2024, previously manufactured lowered-floor wheelchair accessible conversions for selected brands of minivans.

Patient Care

With its *Patient Care* segment, Savaria designs, manufactures, distributes, and installs ceiling lifts, patient transfer slings and accessories, floor lifts and standing aids, bathing equipment, medical beds, therapeutic support surfaces and pressure management products used in healthcare facilities and in home care settings. Savaria operates manufacturing facilities in Canada (Magog and Beamsville), the United States (Greenville and St. Louis) and the United Kingdom (Newton Abbot). The Savaria *Patient Care* product line is sold through institutional and home care sales channels in North America and Europe.

The following tables provide the revenue of Savaria by reportable segment and by region, for the nine-month period ended September 30:

in thousands of dollars, except percentages	YTD 2025					
	Accessibility		Patient Care		Total	
Canada	\$72,984	13.9%	\$51,033	35.2%	\$124,017	18.5%
United States	217,853	41.3%	85,369	59.0%	303,222	45.1%
Europe and rest of world	236,058	44.8%	8,451	5.8%	244,509	36.4%
Total	\$526,895	100.0%	\$144,853	100.0%	\$671,748	100.0%

	YTD 2024					
	Accessibility		Patient Care		Total	
Canada	\$65,989	13.1%	\$46,703	33.2%	\$112,692	17.5%
United States	205,148	40.7%	86,662	61.5%	291,810	45.3%
Europe and rest of world	232,448	46.2%	7,472	5.3%	239,920	37.2%
Total	\$503,585	100.0%	\$140,837	100.0%	\$644,422	100.0%

5. Financial Highlights

in thousands of dollars, except percentages and per-share amounts	Q3		YTD	
	2025	2024	2025	2024
Revenue	\$224,770	\$213,634	\$671,748	\$644,422
Gross Profit	88,124	79,120	259,865	237,488
Operating income	\$27,695	\$22,040	\$75,645	\$62,365
Adjusted EBITDA*	\$47,556	\$41,737	\$134,941	\$118,363
Adjusted EBITDA margin*	21.2%	19.5%	20.1%	18.4%
Net earnings ¹	19,470	11,165	48,265	34,177
Adjusted net earnings*	23,452	15,179	60,797	45,526
Diluted net earnings per share ¹	\$0.27	\$0.16	\$0.67	\$0.48
Adjusted net earnings per share* ¹	\$0.32	\$0.21	\$0.84	\$0.64

* Non-IFRS measures are described and reconciled in sections 3 and 6.

¹ The amounts for 2024 reflect adjustments made for Q3 2024 and YTD 2024 between net finance costs and other comprehensive income, as detailed and explained in section 7.

Q3 2025 HIGHLIGHTS

- Revenue for the quarter was \$224.8M, up \$11.1M or 5.2%, compared to Q3 2024, mainly due to organic growth of 1.8% combined with a positive foreign exchange impact of 2.5%. The revenue from the acquisition of Western Elevator Ltd (“Western”) contributed 0.9% growth.
 - Accessibility* experienced growth of 6.1%, including growth of 7.7% coming from North America combined with growth of 3.6% in Europe.
 - Patient Care* achieved revenue growth of 1.9%.
- Gross profit was \$88.1M, up \$9.0M or 11.4%, compared to Q3 2024, representing a gross margin of 39.2%, an increase of 220 bps compared to 37.0% in Q3 2024.
- Operating income was \$27.7M, up \$5.7M or 25.7%, compared to Q3 2024, representing an operating margin of 12.3% compared to 10.3% in Q3 2024.
- Adjusted EBITDA* was \$47.6M, up \$5.8M or 13.9%, representing \$0.66 per share, up \$0.08, when compared to Q3 2024.
- Adjusted EBITDA margin* stood at 21.2% up 170 bps compared to 19.5% in Q3 2024.
 - Accessibility* adjusted EBITDA* was \$42.3M or 23.5%, an increase of \$6.1M or 16.9% compared to Q3 2024.
 - Patient Care* adjusted EBITDA* was \$8.2M or 18.3%, an increase of \$0.5M or 7.1% compared to Q3 2024.
- Net earnings and adjusted net earnings* for the quarter were \$19.5M and \$23.5M, respectively, or \$0.27 and \$0.32 per share on a diluted basis, compared to \$11.2M and \$15.2M, respectively, or \$0.16 and \$0.21 per share on a diluted basis in Q3 2024.

2025 HIGHLIGHTS YEAR TO DATE

- Revenue was \$671.7M, up \$27.3M or 4.2%, compared to 2024, mainly due to organic growth of 0.6%, a positive foreign exchange impact of 2.8% and the impact of the acquisitions of Western and Matot, partially offset by the divestitures of Van-Action and Freedom Motors.
 - Accessibility* growth of 4.6% driven from 7.5% growth in North America. Europe was flat compared to last year.
 - Patient Care* had revenue growth of 2.9%.

* Non-IFRS measures are described and reconciled in sections 3, 6 and 8.

- Gross profit was \$259.9M, up \$22.4M or 9.4%, compared to 2024, representing a gross margin of 38.7%, an increase of 180 bps compared to 36.9% in 2024.
- Operating income was \$75.6M, up \$13.3M or 21.3%, compared to 2024, representing an operating margin of 11.3% compared to 9.7% in 2024.
- Adjusted EBITDA* was \$134.9M, up \$16.6M or 14.0%, representing \$1.88 per share, up \$0.22, when compared to 2024.
- Adjusted EBITDA margin* stood at 20.1% up 170 bps compared to 18.4% in 2024.
 - *Accessibility* adjusted EBITDA* was \$115.3M or 21.9%, an increase of \$15.3M or 15.3% compared to 2024.
 - *Patient Care* adjusted EBITDA* was \$28.1M or 19.4%, an increase of \$3.2M or 12.9% compared to 2024.
- Net earnings and adjusted net earnings* were \$48.3M and \$60.8M, respectively, or \$0.67 and \$0.84 per share on a diluted basis, compared to \$34.2M and \$45.5M, respectively, or \$0.48 and \$0.64 per share on a diluted basis in 2024.
- The ratio of net debt to adjusted EBITDA* stood at 1.19 in comparison to 1.63 as at December 31, 2024.
- Available funds* of \$293.4M to support working capital, investments and growth opportunities.

6. Financial Review

6.1 REVENUE

During the quarter, the Corporation generated revenue of \$224.8M, up \$11.1M or 5.2%, compared to the same period in 2024. The increase was driven by organic growth of 1.8%, a positive foreign exchange impact of 2.5%, as well as the revenue contribution from the acquisition of Western for 0.9%.

For the nine-month period ended September 30, 2025, the Corporation generated revenue of \$671.7M, up \$27.3M or 4.2%, compared to the same period in 2024. The increase is driven by organic growth of 0.6%, and a positive foreign exchange impact of 2.8%. The net acquisition impact of 0.8% was driven by the acquisition of Western and Matot and was partially offset by the divestitures of Van-Action and Freedom Motors.

The following tables provide a summary of quarterly and year-to-date variances in revenue both by reportable segment and in total.

in thousands of dollars, except percentages	Q3		
	Accessibility	Patient Care	Total
Revenue 2025	\$180,055	\$44,715	\$224,770
Revenue 2024	\$169,769	\$43,865	\$213,634
Net change %	6.1%	1.9%	5.2%
Organic growth ¹	2.0%	1.2%	1.8%
Acquisition/divestiture impact ²	1.1%	0.0%	0.9%
Foreign currency impact ³	3.0%	0.7%	2.5%
Net change %	6.1%	1.9%	5.2%

¹ Organic growth (contraction) represents the revenue growth/decrease coming from the existing entities as of the previous year and is calculated based on local functional currency.

² Acquisition/divestiture impact represents the revenue growth/decrease coming from the newly acquired or divested entities during the last twelve months and is calculated based on local functional currency.

³ Foreign currency impact represents the foreign exchange impact unrelated to organic growth (contraction) and acquisition/divestiture.

* Non-IFRS measures are described and reconciled in sections 3, 6 and 8.

in thousands of dollars, except percentages	YTD		
	Accessibility	Patient Care	Total
Revenue 2025	\$526,895	\$144,853	\$671,748
Revenue 2024	\$503,585	\$140,837	\$644,422
Net change %	4.6%	2.9%	4.2%
Organic growth ¹	0.5%	0.9%	0.6%
Acquisition/divestiture impact ²	1.0%	0.0%	0.8%
Foreign currency impact ³	3.1%	2.0%	2.8%
Net change %	4.6%	2.9%	4.2%

¹ Organic growth (contraction) represents the revenue growth/decrease coming from the existing entities as of the previous year and is calculated based on local functional currency.

² Acquisition/divestiture impact represents the revenue growth/decrease coming from the newly acquired or divested entities during the last twelve months and is calculated based on local functional currency.

³ Foreign currency impact represents the foreign exchange impact unrelated to organic growth (contraction) and acquisition/divestiture.

6.1.1 Accessibility

Revenue from our *Accessibility* segment was \$180.1M for the quarter, an increase of \$10.3M or 6.1%, compared to the same period in 2024. The increase in revenue was due to organic growth of 2.0% consisting of 5.5% growth in North America and a contraction of 2.9% in Europe and a positive foreign exchange impact of 3.0%, mainly coming from the GBP, EUR and USD currencies. North America was able to deliver revenue growth in challenging markets in the United States and Canada. The revenue contraction in Europe is mainly due to the Corporation's focus on higher margin contracts in a competitive environment. In addition, revenues benefited from the acquisition of Western.

For the nine-month period ended September 30, 2025, revenue from our *Accessibility* segment was \$526.9M, an increase of \$23.3M, or 4.6%, compared to the same period in 2024. The increase in revenue was related to organic growth of 0.5%, derived from organic growth of 4.6% in North America and an organic contraction of 5.6% in Europe combined with a positive foreign exchange impact of 3.1%. The growth resulting from the acquisitions of Western and Matot, was partially offset by the divestitures of Van-Action, Freedom Motors.

6.1.2 Patient Care

Revenue from our *Patient Care* segment was \$44.7M for the quarter, an increase of \$0.9M or 1.9% compared to the same period in 2024. The revenue increase is mainly due to organic growth of 1.2% combined with a positive foreign exchange impact of 0.7%. The revenue growth is mainly driven by increased sales within the United States.

For the nine-month period ended September 30, 2025, revenue from our *Patient Care* segment was \$144.9M, an increase of \$4.0M, or 2.9%, compared to the same period in 2024. The increase in revenue was mainly driven by organic growth of 0.9% and a positive foreign exchange impact of 2.0%.

6.2 GROSS PROFIT AND OPERATING INCOME

in thousands of dollars, except per-share amounts and % revenue	Q3				YTD			
	2025		2024		2025		2024	
Revenue	\$224,770		\$213,634		\$671,748		\$644,422	
Cost of sales	136,646	60.8%	134,514	63.0%	411,883	61.3%	406,934	63.1%
Gross Profit	\$88,124	39.2%	\$79,120	37.0%	\$259,865	38.7%	\$237,488	36.9%
Selling and administrative expenses	55,110	24.5%	51,620	24.2%	167,460	24.9%	159,444	24.7%
Strategic initiatives expenses	4,672	2.1%	5,413	2.5%	13,949	2.1%	16,059	2.5%
Other expenses (income)	647	0.3%	47	0.0%	2,811	0.4%	(380)	0.0%
Operating income	\$27,695	12.3%	\$22,040	10.3%	\$75,645	11.3%	\$62,365	9.7%
Net finance costs ¹	2,191	1.0 %	6,911	3.2%	10,367	1.6%	16,066	2.5%
Earnings before income tax ¹	\$25,504	11.3%	\$15,129	7.1%	\$65,278	9.7%	\$46,299	7.2%
Income tax expense ¹	6,034	2.6%	3,964	1.9%	17,013	2.5%	12,122	1.9%
Net Earnings ¹	\$19,470	8.7%	\$11,165	5.2%	\$48,265	7.2%	\$34,177	5.3%
Adjusted EBITDA*	\$47,556	21.2%	\$41,737	19.5%	\$134,941	20.1%	\$118,363	18.4%
Basic net earnings per share ¹	\$0.27		\$0.16		\$0.68		\$0.48	
Diluted net earnings per share ¹	\$0.27		\$0.16		\$0.67		\$0.48	

* Non-IFRS measures are described and reconciled in section 3.

¹ The Q3 2024 and YTD 2024 amounts reflect adjustments made between net finance costs and other comprehensive income, as detailed and explained in section 7.

For the quarter, the increase in gross profit of \$9.0M when compared to the same period in 2024, is attributable to improved gross margins in both segments due to operating leverage, improved pricing, and procurement benefits. For the nine-month period ended September 30, 2025, gross margin benefited from the same impacts as listed for the quarter, when compared to the same period in 2024.

For the quarter, selling and administrative expenses as a percentage of revenue were slightly higher when compared to the same period in 2024, and the increase in amount is mainly due to increased employee costs and professional fees, reflecting investments made under *Savaria One*. For the nine-month period ended September 30, 2025, selling and administrative expenses as a percentage of revenue were slightly higher by 20 bps, when compared to the same period in 2024, caused by the same impacts as noted for the quarter.

For the quarter, the Corporation incurred \$0.6M in other expenses, including \$0.4M for optimization programs, \$0.1M in acquisition costs mainly for the acquisition of Western and \$0.1M in integration costs related to the integration of Western. In addition, \$4.7M was incurred in strategic initiative expenses in the quarter. For the nine-month period ended September 30, 2025, the Corporation had other expenses of \$2.8M which mainly related to the acquisition and integration costs of Western and Matot as well as optimization programs. In addition, the Corporation also incurred \$13.9M in strategic initiative expenses, compared to \$16.1M last year.

Consequently, operating income was \$27.7M for the quarter, an increase of \$5.7M when compared to \$22.0M for the same period in 2024. For the nine-month period ended September 30, 2025, operating income was \$75.6M, an increase of \$13.3M when compared to 2024. Quarterly and year-to-date, the increase was mainly attributable to the additional revenue contribution and higher gross margins while partially offset by increased selling and administrative expenses and other expenses.

6.3 ADJUSTED EBITDA

Adjusted EBITDA* and adjusted EBITDA margin* for the quarter stood at \$47.6M and 21.2%, respectively, compared to \$41.7M and 19.5% for the same period in 2024. The increased profitability is mainly explained by the aforementioned increase in gross margin for both segments.

* Non-IFRS measures are described and reconciled in sections 3 and 6.

For the nine-month period ended September 30, 2025, adjusted EBITDA* and adjusted EBITDA margin* stood at \$134.9M and 20.1%, respectively, compared to \$118.4M and 18.4% for the same period in 2024. The year-to-date increase in adjusted EBITDA* and adjusted EBITDA margin* when compared to the prior year is explained by improved performance in both segments, including all regions in *Accessibility*.

Head office costs for the three and nine-month periods ended September 30, 2025 stood at \$2.9M and \$8.4M respectively versus \$2.1M and \$6.5M for the same period in 2024, mainly due to increased employee costs and professional fees. These costs are in line with management's expectations for the year.

The following tables provide a summary of quarterly and year-to-date adjusted EBITDA*, by reportable segment and in total.

in thousands of dollars, except percentages	Q3 2025			Total
	Accessibility	Patient Care	Head Office	
Revenue	\$180,055	\$44,715	n/a	\$224,770
Adjusted EBITDA*	\$42,327	\$8,166	\$(2,937)	\$47,556
Adjusted EBITDA Margin*	23.5%	18.3%	n/a	21.2%
Q3 2024				
Revenue	\$169,769	\$43,865	n/a	\$213,634
Adjusted EBITDA*	\$36,217	\$7,627	\$(2,107)	\$41,737
Adjusted EBITDA Margin*	21.3%	17.4%	n/a	19.5%
YTD 2025				
Revenue	\$526,895	\$144,853	n/a	\$671,748
Adjusted EBITDA*	\$115,288	\$28,064	\$(8,411)	\$134,941
Adjusted EBITDA Margin*	21.9%	19.4%	n/a	20.1%
YTD 2024				
Revenue	\$503,585	\$140,837	n/a	\$644,422
Adjusted EBITDA*	\$99,959	\$24,866	\$(6,462)	\$118,363
Adjusted EBITDA Margin*	19.8%	17.7%	n/a	18.4%

* Non-IFRS measures are described and reconciled in section 3.

6.3.1 Accessibility

For the quarter, *Accessibility* adjusted EBITDA* and adjusted EBITDA margin* stood at \$42.3M and 23.5%, respectively, compared to \$36.2M and 21.3% for the same period in 2024. The increase in adjusted EBITDA* and adjusted EBITDA margin* was mainly due to improved pricing on products delivered, lower material costs and operational efficiencies for both geographical regions. The adjusted EBITDA margins* for both North America and Europe have increased and are materially improved from a year ago.

For the nine-month period ended September 30, 2025, adjusted EBITDA* and adjusted EBITDA margin* stood at \$115.3M and 21.9%, respectively, compared to \$100.0M and 19.8% for the same period in 2024. The increase in the margin is mainly explained by the factors mentioned above for the quarter as well as increased revenue contributing to further operating leverage. On a year-to-date basis, the adjusted EBITDA margin* for North America improved, while the margin considerably increased in Europe.

* Non-IFRS measures are described and reconciled in sections 3 and 6.

6.3.2 Patient Care

For the quarter, *Patient Care* adjusted EBITDA* and adjusted EBITDA margin* stood at \$8.2M and 18.3%, respectively, compared to \$7.6M and 17.4% for the same period in 2024. The increase in both measures was mainly due to pricing initiatives, favorable product mix on certain projects versus last year and lower material costs.

For the nine-month period ended September 30, 2025, adjusted EBITDA* and adjusted EBITDA margin* stood at \$28.1M and 19.4%, respectively, compared to \$24.9M and 17.7% for the same period in 2024. The increase in both metrics is mainly explained by the factors mentioned above for the quarter.

6.4 NET FINANCE COSTS

The Corporation's finance costs relate mainly to interest expenses incurred on credit facilities and leases, amortization of deferred financing fees, general bank charges and realized and unrealized foreign exchange gains or losses pertaining to financial instruments. The Corporation uses its credit facilities to manage working capital, capital expenditures and to finance business acquisitions.

For the quarter, net finance costs were \$2.2M compared to \$6.9M for the same period in 2024. Interest on long-term debt decreased by \$1.7M when compared to 2024 due to the reduced balance of debt and a reduction in variable interest rates. Net finance costs were favorably impacted by a foreign currency gain of \$1.1M compared to a loss of \$1.7M in 2024, most of which was unrealized in nature.

For the nine-month period ended September 30, 2025, net finance costs were \$10.4M compared to \$16.1M for the same period in 2024. The decrease in net finance costs was mainly due to lower interest on long-term debt of \$4.6M as stated above, partially offset by higher interest on lease liabilities and a net foreign currency gain of \$1.0M compared to a loss of \$0.6M in 2024, most of which was unrealized in nature. The Corporation also incurred a net loss on financial instruments of \$0.9M compared to a loss of \$0.8M last year.

6.5 INCOME TAXES

For the quarter, an income tax expense of \$6.0M was recorded on earnings before income taxes of \$25.5M, representing an effective tax rate of 23.7%, compared to an income tax expense of \$4.0M and an effective tax rate of 26.2% for the same period in 2024. For the nine-month period ended September 30, 2025, an income tax expense of \$17.0M was recorded on earnings before taxes of \$65.3M, representing an effective tax rate of 26.1%, whereas the effective tax rate was 26.2% for the same period in 2024. The variances in income tax expense and effective tax rates are the results of different profit allocation coming from countries in which the Corporation operates which are taxable at varying rates, non-deductible expenses, valuation allowance adjustments and withholding tax on repatriation from a foreign subsidiary.

6.6 NET EARNINGS AND ADJUSTED NET EARNINGS

in thousands of dollars, except number of shares and per-share amounts	Q3		YTD	
	2025	2024	2025	2024
Net earnings ¹	\$19,470	\$11,165	\$48,265	\$34,177
Strategic initiatives expenses	4,672	5,413	13,949	16,059
Other expenses (income)	647	47	2,811	(380)
Income tax related to strategic initiatives and other expenses ²	(1,337)	(1,446)	(4,228)	(4,330)
Adjusted net earnings* ¹	\$23,452	\$15,179	\$60,797	\$45,526
In \$ per share				
Diluted net earnings ¹	\$0.27	\$0.16	\$0.67	\$0.48
Strategic initiatives and other expenses net of income tax ²	0.05	0.05	0.17	0.16
Adjusted net earnings* ¹	\$0.32	\$0.21	\$0.84	\$0.64
Diluted weighted average number of shares	72,160,540	71,811,980	71,956,011	71,442,982

* Non-IFRS measures are described in section 3 and reconciled in this section.

¹ The Q3 2024 and YTD 2024 amounts reflect adjustments made between net finance costs and other comprehensive income, as detailed and explained in Section 7.

² Income tax is calculated at the statutory rate in the country where each expense has been incurred.

* Non-IFRS measures are described and reconciled in sections 3, 6 and 8.

For the quarter, net earnings were \$19.5M or \$0.27 per share on a diluted basis, compared to \$11.2M or \$0.16 per share for the same period in 2024. The increase in net earnings was mainly due to higher adjusted EBITDA*, lower strategic initiative expenses and lower net finance costs, partially offset by higher income tax expenses. For the nine-month period ended September 30, 2025, net earnings stood at \$48.3M, or \$0.67 per share on a diluted basis, compared to \$34.2M or \$0.48 for the same period in 2024. The increase in net earnings and net earnings per share on a diluted basis was attributable to the same factors as listed above for the quarter.

For the quarter, adjusted net earnings* were \$23.5M or \$0.32 per share on a diluted basis, compared to \$15.2M or \$0.21 per share for the same period in 2024. For the nine-month period ended September 30, 2025, adjusted net earnings stood at \$60.8M, or \$0.84 per share on a diluted basis, compared to \$45.5M or \$0.64 for the same period in 2024.

7. Summary of Quarterly Results

Selected financial information for the last eight quarters is presented in the following table.

in thousands of dollars, except percentages and per- share amounts	Total	2025				2024		2023	
	Trailing 12 months	Q3	Q2	Q1	Q4	Q3	Q2	Q1	Q4
Revenue	\$895,088	\$224,770	\$226,746	\$220,232	\$223,340	\$213,634	\$221,344	\$209,444	\$216,839
Gross Margin	38.4%	39.2%	39.0%	37.8%	37.7%	37.0%	37.5%	36.0%	34.3%
Operating Income	\$97,417	\$27,695	\$26,712	\$21,238	\$21,772	\$22,040	\$22,604	\$17,721	\$19,843
Adjusted EBITDA*	\$177,808	\$47,556	\$46,738	\$40,647	\$42,867	\$41,737	\$41,945	\$34,681	\$35,105
Adjusted EBITDA Margin*	19.9%	21.2%	20.6%	18.5%	19.2%	19.5%	19.0%	16.6%	16.2%
Net earnings ¹	\$62,598	\$19,470	\$16,316	\$12,479	\$14,333	\$11,165	\$11,383	\$11,629	\$10,959
Net earnings per share - diluted ¹	\$0.87	\$0.27	\$0.23	\$0.17	\$0.20	\$0.16	\$0.16	\$0.16	\$0.16
Dividend declared per share	\$0.542	\$0.137	\$0.135	\$0.135	\$0.135	\$0.131	\$0.130	\$0.130	\$0.130

* Non-IFRS measures are described and reconciled in section 3.

¹ As a result of the change in the presentation of a financial instrument between net finance costs and other comprehensive income, Q1, Q2 and Q3 2024 figures were restated. The impact on Q1 figures were \$(0.8M) on net finance costs and \$0.2M on income tax expense, for net impact on earnings of \$0.6M. The impact on Q2 figures were \$(0.6M) on net finance costs and \$0.2M on income tax expense, for net impact on earnings of \$0.4M. The impact on Q3 figures were \$2.5M on net finance costs and \$(0.7M) on income tax expense, for net impact on earnings of \$(1.9M).

The Corporation experiences seasonal variations in its business. In terms of revenues, excluding the impact of acquisitions and divestitures, the first half of the year is typically weaker than the second half of the year.

* Non-IFRS measures are described and reconciled in sections 3 and 6.

8. Financial Position

8.1 CAPITAL RESOURCES

The Corporation believes its cash flows from operating activities, combined with its available short-term capital resources, will enable it to support its growth strategy, working capital requirements and planned capital expenditures.

The credit facility is available for general corporate purposes and for financing business acquisitions. Under the revolving facility, the Corporation is required, among other conditions, to respect certain covenants on a consolidated basis. Management reviews compliance with these covenants in conjunction with quarterly filing requirements under its revolving facility. All covenants were met as at September 30, 2025.

in thousands of dollars, except ratio	September 30, 2025	December 31, 2024
Total amount available under the revolving facility	\$450,000	\$450,000
Amount drawn under the revolving facility	(204,382)	(239,112)
Outstanding letters of credit	(3,351)	(3,301)
Available credit facilities*	\$242,267	\$207,587
Cash and cash equivalents	51,133	35,242
Available funds*	\$293,400	\$242,829
Current assets	\$323,544	\$325,721
Current liabilities	176,229	179,747
Working capital*	\$147,315	\$145,974
Ratio of current assets to current liabilities	1.84	1.81

* Non-IFRS measures are described in section 3 and reconciled in this section.

8.2 NET DEBT

As at September 30, 2025, the Corporation had a net debt* position of \$211.0M, compared to \$262.7M as of December 31, 2024. The decrease in net debt* of \$51.7M is mainly driven by a reimbursement on the revolving facility of \$30.0M, combined with increased cash and cash equivalents and a positive impact from translation of debt denominated in foreign currencies.

in thousands of dollars, except ratio	September 30, 2025	December 31, 2024
Amount drawn under the revolving facility	\$204,382	\$239,112
Notes payable related to business acquisitions	2,249	2,472
Outstanding letters of credit	3,351	3,301
Lease liabilities	52,179	53,088
Total debt*	\$262,161	\$297,973
Less: Cash and cash equivalents	(51,133)	(35,242)
Net debt*	\$211,028	\$262,731
Trailing twelve months adjusted EBITDA*	177,808	161,230
Ratio of net debt to adjusted EBITDA*	1.19	1.63

* Non-IFRS measures are described in section 3 and reconciled in this section.

* Non-IFRS measures are described and reconciled in sections 3 and 8.

9. Liquidity

in thousands of dollars	Q3		YTD	
	2025	2024	2025	2024
Cash flows related to operating activities before net changes in non-cash operating items	\$37,943	\$30,480	\$101,750	\$80,993
Net changes in non-cash operating items	3,599	5,324	1,309	4,904
Cash flows related to operating activities	41,542	35,804	103,059	85,897
Cash flows related to investing activities	(5,350)	(5,920)	(13,144)	(14,888)
Cash flows related to financing activities	(25,236)	(15,396)	(75,512)	(67,592)
Unrealized foreign exchange impact on cash held in foreign currencies	1,267	128	1,488	797
Net change in cash	\$12,223	\$14,616	\$15,891	\$4,214

9.1 OPERATING ACTIVITIES

For the quarter, cash related to operating activities before net changes in non-cash operating items reached \$37.9M, versus \$30.5M for the same period of 2024, mainly explained by higher net earnings generated combined with lower income taxes paid. Net changes in non-cash operating items increased liquidity by \$3.6M, compared to an increase of \$5.3M a year earlier. The increase in 2025 was driven by reduced trade receivables offset by increased prepaid expenses. As a result, cash generated from operating activities in Q3 2025 stood at \$41.5M, compared to \$35.8M for the same period in 2024.

For the nine-month period ended September 30, 2025, cash related to operating activities before net changes in non-cash operating items reached \$101.8M, versus \$81.0M for the same period in 2024, mainly explained by the same factors mentioned above for the quarter. Net changes in non-cash operating items increased liquidity by \$1.3M, compared to an increase of \$4.9M a year earlier, due to lower trade receivables offset by a decrease in accounts payables. As a result, cash generated from operating activities stood at \$103.1M, compared to \$85.9M for the same period in 2024.

9.2 INVESTING ACTIVITIES

For the quarter, cash used in investing activities was \$5.4M compared to cash used of \$5.9M in 2024. We disbursed \$5.7M for fixed and intangible assets in 2025, compared to \$6.0M for fixed and intangible assets in 2024.

For the nine-month period ended September 30, 2025, cash used in investing activities was \$13.1M compared to \$14.9M in 2024. In 2025, the Corporation disbursed \$4.0M for business acquisition activities, mainly related to Western combined with disbursements of \$15.2M for fixed and intangible assets compared to \$14.4M in 2024. The Corporation received \$5.0M following the settlement of derivative financial instruments in 2025 and \$6.6M from the divestiture of Van-Action and Freedom Motors in 2024.

9.3 FINANCING ACTIVITIES

For the quarter, cash used in financing activities was \$25.2M compared to \$15.4M in 2024. The variation is mainly explained by a reimbursement on the revolving facility of \$11.5M compared to \$3.3M in 2024. The Corporation also paid \$0.3M less for leases when compared to last year, and paid \$1.1M less in interest. The Corporation also received \$1.8M from the proceeds of the exercise of stock options compared to \$4.2M a year earlier.

For the nine-month period ended September 30, 2025, cash used in financing activities was \$75.5M compared to \$67.6M in 2024. The year-to-date variation is also explained by a reimbursement on the revolving facility of \$30.0M compared to \$25.7M in 2024. The Corporation also received \$2.3M from the proceeds of the exercise of stock options compared to \$6.3M, and paid \$3.5M less in interest.

9.4 DIVIDENDS

The aggregate monthly dividends declared in the third quarter and nine months of 2025 totaled \$9.8M and \$29.1M respectively, compared to \$9.4M and \$27.8M for the same period of 2024, mainly explained by the dividend increase on September 30, 2024. As at September 30, 2025, 71,573,331 shares were issued and outstanding, compared to 71,365,841 as at September 30, 2024.

9.5 STOCK OPTIONS

As at November 5, 2025, 4,384,271 stock options were outstanding with exercise prices ranging from \$11.06 to \$22.28.

10. Governance

In compliance with the Canadian Securities Administrators' Regulation 52-109, the Corporation has filed certifications signed by the President and Chief Executive Officer ("CEO") and the Chief Financial Officer ("CFO") that, among other things, report on disclosure controls and procedures ("DC&P") and the design of internal controls over financial reporting ("ICFR").

DC&P are designed to provide reasonable assurance that all relevant information is gathered and reported to senior management, including the CEO and the CFO, on a timely basis to ensure appropriate decisions can be made regarding public disclosure.

ICFR are processes designed to provide reasonable assurance regarding the reliability of financial reporting and compliance with GAAP of the Corporation's consolidated financial statements.

The Corporation has limited the scope of its disclosure controls and procedures and internal controls over financial reporting to exclude controls, policies, and procedures of Western, acquired not more than 365 days before the last day of the period covered by the interim filing. The Corporation elected to exclude it from the scope of certification as allowed by NI 52-109. The Corporation intends to evaluate the situation within one year of the date of acquisition of Western.

There have been no significant changes in our ICFR during the period covered by this MD&A that have materially affected, or are reasonably likely to materially affect, the Corporation's ICFR.

11. Material Accounting Policies and Estimates

Accounting Estimates and Judgements

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Important judgements made by management when applying accounting policies that have the most significant impact on amounts recognized in the consolidated financial statements are the determination of cash-generating units ("CGU"), the identification of operating segments and the determination of foreign operations' functional currencies.

Assumptions and estimate uncertainties that have a significant risk of resulting in a material adjustment are the evaluation of the worldwide deferred income tax balances and income tax expense. Judgements such as interpretations of laws, treaties and regulations in each jurisdiction are also required by management in determining the deferred income tax balances and income tax expense. Other areas involving assumptions and estimate uncertainties include the estimation of the fair value of assets and liabilities acquired during business acquisitions, the determination of the warranty, the inventory obsolescence provisions, the capitalization of intangible assets and the measurement of lease obligations.

12. Risks and Uncertainties

Savaria is engaged in an industry exposed to various risks and uncertainties. The Corporation's operating results and financial position could be adversely affected by each of the risks and uncertainties described in its 2024 annual Management Discussion and Analysis Report, which are incorporated herein by reference:

- Economic Conditions
- Operating Results
- Financing
- Acquisitions
- Currency Fluctuations
- Market and Competition
- Catastrophic Events, Natural Disasters, Severe Weather and Disease
- Healthcare Reimbursement
- Property Rights
- Credit Risk
- Interest Rates Fluctuations
- Price Variation
- Dependence on Key Personnel
- Dependence on Key Distributors
- Dependence on Key Suppliers
- Laws and Regulations
- Product Liability
- Litigation
- Information Systems and Cybersecurity

13. Environmental, Social and Governance ("ESG") Values

As a global leader within the accessibility industry, Savaria is committed to minimizing its environmental footprint and upholding the highest social and governance standards. We believe that promoting environmentally and socially responsible behaviour across our organization is key to achieving sustainable growth and long-term value creation.

By delivering products and solutions that promote accessibility, health, and wellness, improving operational efficiencies and resource usage, and engaging our employees and stakeholders, we'll create a stronger, more resilient business that will continue to be an industry leader while delivering positive social change.

We recognize this work requires long-term vision, planning, and collaboration, yet also must be grounded in clear actions and an ongoing commitment to transparency.

To that end, on April 30, 2025 Savaria published its second ESG report for the fiscal year ended December 31, 2024. Through this report, Savaria outlines its strategy and initiatives on ESG matters that are important to its stakeholders, and where it sees an opportunity to have a positive and meaningful influence. The 2024 ESG report can be found under the investor relations section of our website at savaria.com.

14. Outlook

Savaria's fiscal 2025 forecast projects revenue of approximately \$925M, with an adjusted EBITDA margin* slightly above 20%. This revenue forecast is driven by volume and price increases, new product launches, the acquisition of Western, and favorable foreign exchange effects across the *Accessibility* and *Patient Care* segments.

Despite geopolitical uncertainties, the completion of *Savaria One* positions us well to sustain profitability. Structural improvements have enhanced production capacity, increased operational efficiencies, and generated meaningful cost savings through streamlined procurement.

As one of the global leaders in the accessibility industry with extensive operations in Canada and the United States, Savaria is assessing its supply chain and evaluating and implementing strategies to optimize its North American manufacturing footprint. These efforts aim to maintain competitiveness and ensure continued service for our valued dealer partners.

The above-mentioned outlook is a "forward-looking statement" within the meaning of the securities laws of Canada and subject to the Corporation's disclosure statement.

* Non-IFRS measures are described and reconciled in sections 3 and 6.

2025

SAVARIA CORPORATION

Interim Condensed Consolidated Financial Statements

As at September 30, 2025

(Unaudited and not reviewed by the Corporation's independent auditors)

SAVARIA CORPORATION
INTERIM CONSOLIDATED STATEMENTS OF FINANCIAL POSITION
(in thousands of Canadian dollars - Unaudited)


	<i>Note</i>	September 30, 2025	December 31, 2024
Assets			
Current assets			
Cash and cash equivalents		\$ 51,133	\$ 35,242
Trade and other receivables		105,070	112,441
Income taxes receivable		979	4,577
Derivative financial instruments	11	259	13,272
Inventories		151,519	146,203
Prepaid expenses and other current assets		14,584	13,986
Total current assets		323,544	325,721
Non-current assets			
Derivative financial instruments	11	134	-
Fixed assets		64,998	64,660
Right-of-use assets		49,284	50,553
Intangible assets		200,116	201,557
Goodwill		453,469	429,977
Other long-term assets		882	867
Deferred tax assets		42,977	40,874
Total non-current assets		811,860	788,488
Total assets		\$ 1,135,404	\$ 1,114,209
Liabilities			
Current liabilities			
Trade and other payables		\$ 106,107	\$ 110,640
Dividend payable		3,338	3,208
Income taxes payable		5,801	5,914
Deferred revenues		39,457	36,717
Derivative financial instruments	11	4,564	6,648
Current portion of long-term debt	5	2,027	2,046
Current portion of lease liabilities		11,276	11,066
Provisions		3,659	3,508
Total current liabilities		176,229	179,747
Non-current liabilities			
Long-term debt	5	202,833	237,488
Lease liabilities		40,903	42,022
Long-term provisions		6,144	5,916
Other long-term liabilities		21,417	18,514
Derivative financial instruments	11	4,650	2,302
Deferred tax liabilities		51,519	52,953
Total non-current liabilities		327,466	359,195
Total liabilities		503,695	538,942
Equity			
Share capital	6	562,759	560,002
Contributed surplus		12,876	11,283
Accumulated other comprehensive income (loss)		28,987	(3,901)
Retained earnings		27,087	7,883
Total equity		631,709	575,267
Total liabilities and equity		\$ 1,135,404	\$ 1,114,209

The accompanying notes are an integral part of the interim unaudited condensed consolidated financial statements.

SAVARIA CORPORATION
INTERIM CONSOLIDATED STATEMENTS OF EARNINGS
(in thousands of Canadian dollars, except per share amounts and numbers of shares - Unaudited)


	Note	Three months ended September 30,		Nine months ended September 30,	
		2025	2024 ¹	2025	2024 ¹
Revenue	12	\$ 224,770	\$ 213,634	\$ 671,748	\$ 644,422
Cost of sales		136,646	134,514	411,883	406,934
Gross profit		88,124	79,120	259,865	237,488
Operating expenses					
Selling and administrative expenses		55,110	51,620	167,460	159,444
Strategic initiatives expenses	7	4,672	5,413	13,949	16,059
Other expenses (income)	8	647	47	2,811	(380)
Total operating expenses		60,429	57,080	184,220	175,123
Operating income		27,695	22,040	75,645	62,365
Net finance costs	9	2,191	6,911	10,367	16,066
Earnings before income tax		25,504	15,129	65,278	46,299
Income tax expense		6,034	3,964	17,013	12,122
Net earnings		\$ 19,470	\$ 11,165	\$ 48,265	\$ 34,177
Earnings per share:					
Basic		\$ 0.27	\$ 0.16	\$ 0.68	\$ 0.48
Diluted		\$ 0.27	\$ 0.16	\$ 0.67	\$ 0.48
Basic weighted average number of shares		71,485,282	71,128,617	71,476,676	71,020,962
Diluted weighted average number of shares		72,160,540	71,811,980	71,956,011	71,442,982

¹ The three and nine months of 2024 amounts reflect adjustments made between net finance costs and other comprehensive income, as detailed and explained in Note 9.

The accompanying notes are an integral part of the interim unaudited condensed consolidated financial statements.

	Note	Three months ended September 30,		Nine months ended September 30,	
		2025	2024 ¹	2025	2024 ¹
Net earnings		\$ 19,470	\$ 11,165	\$ 48,265	\$ 34,177
Items that are or may be reclassified subsequently to net earnings:					
Net change in derivative financial instruments designated as cash flow hedges, net of tax		(704)	407	2,152	(1,726)
Net change on translation of financial statements of foreign operations, net of tax		11,067	12,801	31,440	18,694
Costs of hedging reserve on net change in cross-currency swaps designated in net investment hedges, net of tax		9	106	(31)	128
Net change in net investment hedges, net of tax		(4,428)	38	(673)	(4,669)
Other comprehensive income		5,944	13,352	32,888	12,427
Total comprehensive income		\$ 25,414	\$ 24,517	\$ 81,153	\$ 46,604

¹The three and nine months of 2024 amounts reflect adjustments made between net finance costs and other comprehensive income, as detailed and explained in Note 9.

The accompanying notes are an integral part of the interim unaudited condensed consolidated financial statements.

SAVARIA CORPORATION
INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY
Periods of nine months ended September 30, 2025 and 2024
(in thousands of Canadian dollars, except numbers of shares - Unaudited)


	2025					
	Share capital		Contributed surplus	Accumulated other comprehensive income (loss)	Retained earnings	Total equity
	Number	Amount				
Balance at January 1	71,402,507	\$ 560,002	\$ 11,283	\$ (3,901)	\$ 7,883	\$ 575,267
Net earnings	-	-	-	-	48,265	48,265
Stock-based compensation, net of tax	-	-	2,043	-	-	2,043
Exercise of stock options (Note 6)	170,824	2,757	(450)	-	-	2,307
Dividends on common shares (Note 6)	-	-	-	-	(29,061)	(29,061)
Total transactions with shareholders	170,824	2,757	1,593	-	(29,061)	(24,711)
Other comprehensive income	-	-	-	32,888	-	32,888
Balance at September 30	71,573,331	\$ 562,759	\$ 12,876	\$ 28,987	\$ 27,087	\$ 631,709

	2024					
	Share capital		Contributed surplus	Accumulated other comprehensive income (loss) ¹	Retained earnings (deficit) ¹	Total equity
	Number	Amount				
Balance at January 1	70,942,726	\$ 551,355	\$ 9,570	\$ (8,748)	\$ (3,177)	\$ 549,000
Net earnings	-	-	-	-	34,177	34,177
Stock-based compensation, net of tax	-	-	2,039	-	-	2,039
Exercise of stock options (Note 6)	423,115	8,131	(1,448)	-	-	6,683
Dividends on common shares (Note 6)	-	-	-	-	(27,813)	(27,813)
Total transactions with shareholders	423,115	8,131	591	-	(27,813)	(19,091)
Other comprehensive income	-	-	-	12,427	-	12,427
Balance at September 30	71,365,841	\$ 559,486	\$ 10,161	\$ 3,679	\$ 3,187	\$ 576,513

¹The nine months of 2024 amounts reflect adjustments made between net finance costs and other comprehensive income, as detailed and explained in Note 9.

The accompanying notes are an integral part of the interim unaudited condensed consolidated financial statements.

SAVARIA CORPORATION
INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands of Canadian dollars - Unaudited)


		Three months ended September 30,		Nine months ended September 30,	
	Note	2025	2024 ¹	2025	2024 ¹
Cash flows related to operating activities					
Net earnings		\$ 19,470	\$ 11,165	\$ 48,265	\$ 34,177
Adjustments for:					
Depreciation of fixed assets		2,661	2,487	7,966	6,858
Depreciation of right-of-use assets		3,292	3,078	9,793	8,496
Amortization of intangible assets		7,837	7,906	22,650	22,926
Income tax expense		6,034	3,964	17,013	12,122
Gain on business divestitures	8	-	-	-	(879)
Stock-based compensation		752	766	2,127	2,039
Non-cash movements on financial instruments	9	(10)	338	930	885
Loss on the sale and write-off of fixed assets and intangible assets		68	35	127	45
Unrealized foreign exchange loss		137	2,933	930	1,824
Interest and amortization of financing costs	9	3,311	4,950	10,427	14,715
Income tax paid		(5,609)	(7,142)	(18,478)	(22,215)
		37,943	30,480	101,750	80,993
Net changes in non-cash operating items	10	3,599	5,324	1,309	4,904
Net cash related to operating activities		41,542	35,804	103,059	85,897
Cash flows related to investing activities					
Business acquisitions	4	206	-	(3,956)	(7,137)
Proceeds from business divestitures		-	-	746	6,646
Settlement of derivative financial instruments	11	-	-	4,954	-
Proceeds from sale of fixed assets		143	34	331	50
Additions to fixed assets		(3,126)	(3,885)	(7,767)	(8,722)
Increase in intangible assets		(2,573)	(2,069)	(7,452)	(5,725)
Net cash related to investing activities		(5,350)	(5,920)	(13,144)	(14,888)
Cash flows related to financing activities					
Repayment of lease obligations		(3,139)	(3,424)	(10,648)	(9,133)
Net change in the revolving facility	5	(11,492)	(3,311)	(30,021)	(25,653)
Interest paid		(2,472)	(3,598)	(7,910)	(11,395)
Transaction costs related to the revolving facility		(309)	-	(309)	-
Proceeds from exercise of stock options	6	1,827	4,177	2,307	6,266
Dividends paid on common shares	6	(9,651)	(9,240)	(28,931)	(27,677)
Net cash related to financing activities		(25,236)	(15,396)	(75,512)	(67,592)
Unrealized foreign exchange impact on cash held in foreign currencies		1,267	128	1,488	797
Net change in cash		12,223	14,616	15,891	4,214
Cash - Beginning of the period		38,910	43,674	35,242	54,076
Cash - End of the period		\$ 51,133	\$ 58,290	\$ 51,133	\$ 58,290

¹The three and nine months of 2024 amounts reflect adjustments made between net finance costs and other comprehensive income, as detailed and explained in Note 9.

The accompanying notes are an integral part of the interim unaudited condensed consolidated financial statements.

1. Nature of Activities and Corporate Information

Savaria Corporation is domiciled in Canada. The interim condensed consolidated financial statements of the Corporation as at and for the periods ended September 30, 2025 and 2024 comprise the accounts of Savaria Corporation and its wholly owned subsidiaries (together referred to as the "Corporation" or as "Savaria"). Savaria is one of the global leaders in the accessibility industry. It provides accessibility solutions for the elderly and physically challenged to increase their comfort, their mobility and their independence. The activities of the Corporation are divided into two reportable segments: *Accessibility* and *Patient Care* as described in Note 12 - Reportable segments.

The common shares of the Corporation are listed under the trading symbol "SIS" on the Toronto Stock Exchange.

2. Basis of Presentation**A) Statement of Compliance**

The interim condensed consolidated financial statements have been prepared in accordance with IFRS Accounting Standards as issued by the International Accounting Standards Board applicable to the preparation of interim financial statements, including IAS 34.

These interim condensed financial statements do not include all of the information required for full annual financial statements and should be read in conjunction with the audited annual consolidated financial statements of the Corporation and the notes thereto for the year ended on December 31, 2024. These interim condensed financial statements have not been the subject of a review or an audit by the Corporation's auditors; they were approved by the Board of Directors on November 5, 2025.

B) Use of Estimates and Judgements

The preparation of the consolidated financial statements in conformity with IFRS requires management to make judgements, estimates and assumptions that affect the application of accounting policies and the reported amounts of assets, liabilities, revenue and expenses. Actual results may differ from these estimates.

Estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimates are revised and in any future periods affected.

Important judgements made by management when applying accounting policies that have the most significant impact on amounts recognized in the consolidated financial statements are the determination of cash-generating units ("CGU"), the identification of operating segments and the determination of foreign operations' functional currencies.

Assumptions and estimate uncertainties that have a significant risk of resulting in a material adjustment are the determination of worldwide deferred income tax balances and income tax expense. Judgements such as interpretations of laws, treaties and regulations in each jurisdiction are required by management in determining deferred income tax balances and income tax expense. Other areas involving assumptions and estimate uncertainties include the estimation of the fair value of assets and liabilities acquired during business acquisitions, the determination of the warranty, inventory obsolescence provisions, the capitalization of intangible assets and the measurement of lease obligations.

3. Material Accounting Policies

The interim condensed consolidated financial statements have been prepared following the same accounting policies used in the audited annual consolidated financial statements for the year ended December 31, 2024.

The accounting policies have been applied consistently by the Corporation's entities and to all periods presented in these interim condensed consolidated financial statements, unless otherwise indicated.

4. Business Acquisition

Business Acquisition Realized During the Fiscal Year

Western Elevator Ltd

On May 8, 2025, the Corporation acquired all issued shares of Western Elevator Ltd. ("Western") for a purchase price of \$5,436,000. Western is a premier home elevator and lift dealer based in Coquitlam, British Columbia.

The acquisition of Western has been accounted for using the acquisition method. Western has been consolidated from the acquisition date. The purchased assets comprised mainly of right of use assets, intangible assets and goodwill. The goodwill has been allocated to the *Accessibility* reportable segment and is non-deductible for tax purposes. As at September 30, 2025, the remaining balance payable of \$606,000 was presented in short term account payables.

The purchase price allocation is expected to be completed as soon as management has gathered all the information available and considered necessary to finalize the allocation.

5. Long-term Debt

	September 30, 2025	December 31, 2024
Revolving Facility ¹	\$ 202,611	\$ 237,062
Notes payable related to business acquisitions	2,249	2,472
	\$ 204,860	\$ 239,534
Less: Current portion	2,027	2,046
	\$ 202,833	\$ 237,488

¹ Net of deferred financing costs of \$1,771,000 (2024 - \$2,050,000).

Revolving Facility

The Corporation has a revolving facility as follows:

- Amount available of \$450,000,000, in Canadian dollar (or in US dollar, euro or British pound equivalent);
- The revolving facility comes to maturity on August 15, 2028;
- Interest is payable on a monthly basis. The applicable interest rate on the revolving facility is based on the leverage level assigned to the Corporation. According to the current credit rating, the rate is either the CORRA or SOFR, plus 1.50% or 1.30%, respectively, or the Canadian prime rate or US base rate, plus 0.20%, before the impact of the cross-currency swaps;
- As at September 30, 2025, amounts of \$886,000 in CA dollars and \$146,224,000 in US dollars were drawn on the revolving facility.

Reconciliation of movements of long-term debt to cash flows arising from financing activities:

	2025
Balance at January 1	\$ 239,534
Net change in the revolving facility	(30,021)
Note paid related to a previous business acquisition	(210)
Amortization of deferred financing costs	595
Transaction costs related to a long-term debt	(309)
Impact of the change in foreign exchange rates	(4,729)
	\$ 204,860
Less: Current portion	2,027
Balance at September 30	\$ 202,833

6. Share Capital

A) Share Capital and Contributed Surplus

During the first nine months of 2025, the Corporation issued 170,824 common shares (2024-423,115) at an average price of \$13.51 per share (2024-\$15.79) following the exercise of stock options. These exercises resulted in an increase in share capital of \$2,757,000 (2024-\$8,131,000) and a decrease in contributed surplus of \$450,000 (2024-\$1,448,000). The average closing price of the Corporation's shares on the exercise dates of options exercised during 2025 was \$20.02 (2024-\$19.40).

The following table presents the reconciliation of outstanding stock options as at September 30, 2025 and 2024:

		2025		2024
	Number of options	Weighted average exercise price	Number of options	Weighted average exercise price
Outstanding at January 1	3,949,590	\$ 16.75	3,117,450	\$ 15.86
Granted	907,505	19.90	979,921	16.38
Exercised	(170,824)	13.51	(423,115)	15.79
Expired and forfeited	(270,337)	17.24	(105,166)	17.18
Outstanding at September 30	4,415,934	\$ 17.50	3,569,090	\$ 15.98

The value of each option is estimated at the date of grant using the Black-Scholes option pricing model with the following assumptions:

	2025
Number of options granted	907,505
Risk-free interest rate ¹	3.06%
Expected dividend yield ¹	2.73%
Expected volatility ¹	29%
Expected term	4-6 years

¹ Weighted average

The estimated fair value of the options granted in 2025 is \$4,040,000 (2024-\$3,943,000). This amount is amortized and charged to earnings as the rights to exercise are vested.

B) Dividends

The following dividends were declared and paid by the Corporation:

		Nine months ended September 30, 2024
	2025	2024
Dividends declared	\$ 29,061	\$ 27,813
Amount declared per share in cents	40.7	39.1
Dividends paid	\$ 28,931	\$ 27,677
Amount paid per share in cents	40.5	39.0

7. Strategic Initiatives Expenses

In 2023, the Corporation initiated a two-year strategic plan called *Savaria One* to optimize sales and operations. Strategic initiatives expenses are predominantly related to consulting fees for *Savaria One*.

SAVARIA CORPORATION

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Tabular amounts are expressed in thousands of Canadian dollars, except share data - Unaudited)

8. Other Expenses (Income)

Other expenses (income) encompass items of financial performance which the Corporation believes should be separately identified in the consolidated statement of earnings to assist in understanding its operating financial performance.

Business acquisition costs pertain to transaction costs incurred related to business purchases (successful or not). Business integration costs pertain to costs incurred to integrate newly acquired businesses.

Optimization program costs pertain to costs incurred in order to improve the efficiency of operations activities across the business and is comprised mainly of employee termination expenses and relocation costs.

On February 1, 2024, Savaria sold all of the issued and outstanding shares of its wholly-owned subsidiaries, Van-Action and Freedom Motors, to Driverge Canada, a subsidiary of Driverge Vehicle Innovations, LLC. The net gain of \$879,000 from these divestitures was recorded as other income within the caption as of June 30, 2024.

	Three months ended September 30, 2025		Nine months ended September 30, 2024	
	2025	2024	2025	2024
Business acquisition costs	\$ 92	\$ -	\$ 397	\$ 208
Business integration costs	144	47	779	291
Optimization program costs	411	-	1,635	-
Gain on business divestitures	-	-	-	(879)
	\$ 647	\$ 47	\$ 2,811	\$ (380)

9. Net Finance Costs

	Three months ended September 30, 2025		Nine months ended September 30, 2024	
	2025	2024	2025	2024
Interest on long-term debt	\$ 2,492	\$ 4,199	\$ 7,999	\$ 12,594
Interest on lease liabilities	591	548	1,757	1,495
Other interests and bank charges	95	85	365	191
Amortization of deferred financing costs and accretion expenses	228	203	671	626
Interest income	(81)	(167)	(375)	(369)
Net (gain) loss on foreign currency exchange	(1,124)	1,705	(980)	644
Net (gain) loss on financial instruments	(30)	332	870	849
Ineffective portion of changes in fair value of net investment hedges	20	6	60	36
	\$ 2,191	\$ 6,911	\$ 10,367	\$ 16,066

As a result of the change in the presentation of a financial instrument between net finance costs and other comprehensive income, Q3 2024 figures were restated. The impact on Q3 2024 figures were \$(2,532,000) on net finance costs and \$671,000 on income tax expense, for net impact on earnings of \$(1,861,000). For the nine-month period ended September 30, 2024, the impact on Q3 figures were \$(1,166,000) on net finance costs and \$309,000 on income tax expense, for net impact on earnings of \$(857,000). The impact on the accumulated other comprehensive income was \$(915,000) and on the deferred tax assets was \$58,000 as at September 30, 2024.

SAVARIA CORPORATION

NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS

(Tabular amounts are expressed in thousands of Canadian dollars, except share data - Unaudited)

10. Net Changes in Non-cash Operating Items

	Three months ended September 30,		Nine months ended September 30,	
	2025	2024	2025	2024
Trade and other receivables	\$ 6,960	\$ 6,408	\$ 10,153	\$ 10,019
Inventories	(476)	(2,797)	(1,612)	(6,654)
Prepaid expenses and other current assets	(2,200)	4,027	(317)	(408)
Other long-term assets	8	9	23	(16)
Trade and other payables	(156)	(766)	(8,906)	3,814
Deferred revenues	(850)	(1,530)	468	(3,668)
Provisions	(188)	(332)	(174)	(241)
Other long-term liabilities	501	305	1,674	2,058
	\$ 3,599	\$ 5,324	\$ 1,309	\$ 4,904

11. Derivative Financial Instruments

The table below shows the presentation of the derivative financial instruments in the Statement of Financial Position.

	September 30, 2025	December 31, 2024
Current assets		
Foreign exchange contracts	\$ 259	\$ -
Cross-currency swaps	-	13,272
	\$ 259	\$ 13,272
Non-current assets		
Foreign exchange contracts	\$ 134	\$ -
	\$ 134	\$ -
Current liabilities		
Foreign exchange contracts	\$ 371	\$ 6,648
Cross-currency swaps	4,193	-
	\$ 4,564	\$ 6,648
Non-current liabilities		
Foreign exchange contracts	\$ -	\$ 148
Cross-currency swaps	4,650	2,154
	\$ 4,650	\$ 2,302

The only financial instruments of the Corporation that are measured at fair value on a recurring basis subsequent to their initial recognition are derivative financial instruments which are Level 2. The fair value of forward exchange contracts is estimated by discounting the difference between the contractual forward price and the current forward price for the residual maturity of the contract using a risk-free interest rate (based on government bonds). The fair value of cross-currency swaps is calculated as the present value of estimated future cash flows over the remaining term of the contracts and is based on market data (primarily yield curves, interest rates, and exchange rates for cross-currency swaps). Fair values reflect the credit risk of the instrument and include adjustments to take account of the credit risk of the Corporation's subsidiary or counterparty when appropriate. The carrying amount of cash and cash equivalents, trade and other receivables, trade and other payables approximate their fair values due to their short-term maturities. The carrying amount of the long-term debt approximates its fair values since it bears interest at variable rates. For the nine months ended September 30, 2025, a net loss of \$870,000 was recorded in financial expenses related to the change in fair value through earnings of these instruments.

On April 3rd, 2025, the Corporation's EUR 80,000,000 USD-EUR cross-currency swap and EUR 40,000,000 foreign exchange contract matured and were settled. A EUR 40,000,000 portion of this USD-EUR cross-currency swap was part of the hedging item designated in its European operations net investment hedging relationship, and following its maturity, the Corporation designated its EUR 40,000,000 (USD 43,500,000) forward cross-currency swap entered into on January 9, 2024 with an effective date starting on April 3rd, 2025 and maturing on April 3rd, 2027 in its net investment hedge.

12. Reportable Segments

Information About the Reportable Segments

For the purpose of financial reporting, the business is structured into two reportable segments according to their respective addressable markets. The *Accessibility* segment includes the designing, manufacturing, distribution and installation of a wide portfolio of accessibility products including commercial and home elevators, stairlifts, platform lifts and dumbwaiters, for personal, residential or commercial applications. It also sells a wide variety of wheelchair accessible motor vehicles adapted for people with special needs. The *Patient Care* segment includes the designing, manufacturing, distribution, and installation of ceiling lifts, patient transfer slings and accessories, floor lifts, standing aids, bathing equipment, medical beds, therapeutic support surfaces and pressure management products used in healthcare facilities and in home care settings.

The Corporation's management assesses the performance of the reportable segments based on revenue and adjusted EBITDA. Adjusted EBITDA is defined as earnings before net finance costs, taxes, depreciation and amortization, strategic initiatives expenses, other expenses (income) and stock-based compensation expense. Head office costs pertain to expenses for certain corporate functions, which are not allocated to segments.

	Three months ended September 30,			
	Accessibility	Patient Care	Head Office	Total
2025				
Revenue	\$ 180,055	\$ 44,715	\$ -	\$ 224,770
Adjusted EBITDA	\$ 42,327	\$ 8,166	\$ (2,937)	\$ 47,556
Stock-based compensation	-	-	752	752
Strategic initiatives expenses	3,104	493	1,075	4,672
Other expenses	382	164	101	647
Depreciation and amortization expense	10,544	2,346	900	13,790
Operating income	\$ 28,297	\$ 5,163	\$ (5,765)	\$ 27,695
2024				
Revenue	\$ 169,769	\$ 43,865	\$ -	\$ 213,634
Adjusted EBITDA	\$ 36,217	\$ 7,627	\$ (2,107)	\$ 41,737
Stock-based compensation	-	-	766	766
Strategic initiatives expenses	3,378	930	1,105	5,413
Other expenses (income)	91	-	(44)	47
Depreciation and amortization expense	10,270	2,192	1,009	13,471
Operating income	\$ 22,478	\$ 4,505	\$ (4,943)	\$ 22,040

SAVARIA CORPORATION
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(Tabular amounts are expressed in thousands of Canadian dollars, except share data - Unaudited)
12. Reportable Segments (continued)
Information About the Reportable Segments (continued)

	Nine months ended September 30,			
	Accessibility	Patient Care	Head Office	Total
2025				
Revenue	\$ 526,895	\$ 144,853	\$ -	\$ 671,748
Adjusted EBITDA	\$ 115,288	\$ 28,064	\$ (8,411)	\$ 134,941
Stock-based compensation	-	-	2,127	2,127
Strategic initiatives expenses	9,093	1,709	3,147	13,949
Other expenses	1,671	720	420	2,811
Depreciation and amortization expense	30,885	6,755	2,769	40,409
Operating income	\$ 73,639	\$ 18,880	\$ (16,874)	\$ 75,645
2024				
Revenue	\$ 503,585	\$ 140,837	\$ -	\$ 644,422
Adjusted EBITDA	\$ 99,959	\$ 24,866	\$ (6,462)	\$ 118,363
Stock-based compensation	-	-	2,039	2,039
Strategic initiatives expenses	10,948	1,891	3,220	16,059
Other expenses (income)	(764)	-	384	(380)
Depreciation and amortization expense	28,893	6,246	3,141	38,280
Operating income	\$ 60,882	\$ 16,729	\$ (15,246)	\$ 62,365

Disaggregation of Revenue and Information by Geographical Areas

	Three months ended September 30,		
	Accessibility	Patient Care	Total
2025			
Revenue by region			
Canada	\$ 24,952	\$ 14,889	\$ 39,841
United States	74,278	26,602	100,880
Europe and rest of world	80,825	3,224	84,049
	\$ 180,055	\$ 44,715	\$ 224,770
Timing of revenue recognition			
Goods transferred at a point in time	\$ 162,044	\$ 38,431	\$ 200,475
Services provided over time	18,011	6,284	24,295
	\$ 180,055	\$ 44,715	\$ 224,770
2024			
Revenue by region			
Canada	\$ 21,786	\$ 16,153	\$ 37,939
United States	70,858	25,276	96,134
Europe and rest of world	77,125	2,436	79,561
	\$ 169,769	\$ 43,865	\$ 213,634
Timing of revenue recognition			
Goods transferred at a point in time	\$ 152,569	\$ 38,818	\$ 191,387
Services provided over time	17,200	5,047	22,247
	\$ 169,769	\$ 43,865	\$ 213,634

SAVARIA CORPORATION
NOTES TO THE INTERIM CONSOLIDATED FINANCIAL STATEMENTS
(Tabular amounts are expressed in thousands of Canadian dollars, except share data - Unaudited)
12. Reportable Segments (continued)
Disaggregation of Revenue and Information by Geographical Areas (continued)

	Nine months ended September 30,		
	Accessibility	Patient Care	Total
2025			
Revenue by region			
Canada	\$ 72,984	\$ 51,033	\$ 124,017
United States	217,853	85,369	303,222
Europe and rest of world	236,058	8,451	244,509
	\$ 526,895	\$ 144,853	\$ 671,748
Timing of revenue recognition			
Goods transferred at a point in time	\$ 474,959	\$ 127,029	\$ 601,988
Services provided over time	51,936	17,824	69,760
	\$ 526,895	\$ 144,853	\$ 671,748
2024			
Revenue by region			
Canada	\$ 65,989	\$ 46,703	\$ 112,692
United States	205,148	86,662	291,810
Europe and rest of world	232,448	7,472	239,920
	\$ 503,585	\$ 140,837	\$ 644,422
Timing of revenue recognition			
Goods transferred at a point in time	\$ 454,277	\$ 124,345	\$ 578,622
Services provided over time	49,308	16,492	65,800
	\$ 503,585	\$ 140,837	\$ 644,422



SAVARIA CORPORATION

4350 Highway 13 Laval QC H7R 6E9 Canada

450.681.5655

800.931.5655

savaria.com

